CAR-T Cell Therapy for Advanced Light Chain Amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a biopsy-confirmed diagnosis of light chain amyloidosis (a disease where abnormal proteins build up in organs and tissues)
- Your amyloidosis must have come back or stopped responding after at least 2 prior treatment regimens
- You must have a high level of disease marker (dFLC >50 mg/L) in your blood
- Your organ function must be adequate: reasonable kidney, liver, and heart function with good blood counts
- You must be expected to live at least 12 weeks and be able to perform light daily activities (ECOG ≤2)
- Women of childbearing age must use effective birth control for 1 year after the cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.